ArticleBiochemistry and biophysics reports2026
Innate immune overactivation hinders nuclear reprogramming through IFN-IFNAR1 axis.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear reprogramming to pluripotency holds great promise for regenerative medicine. However, innate immune overactivation may impair nuclear reprogramming efficiency but the underlying mechanism is not fully understood. Here we used mouse embryonic fibroblasts isolated from doxycycline-inducible OSKM transgenic mice as the nuclear reprogramming system and administered a high dosage of Polyinosinic polycytidylic acid (PIC) to stimulate TLR3 as the innate immune overactivation. PIC treatment reduced nuclear reprogramming efficiency. We identified that PIC treatment upregulated type I interferon transcription and secretion, IFNAR1 cell surface expression, and nuclear Stat1 level. Importantly, the introduction of Ifnar1 blocking antibody completely reversed this impaired nuclear reprogramming efficiency. Similarly, Ifn-β neutralizing antibody substantially ameliorated the impaired nuclear reprogramming efficiency caused by PIC treatment. Our data suggest that innate immune overactivation impairs nuclear reprogramming through the IFN-IFNAR1 axis. Blocking this signaling pathway can be used as a general strategy to enhance nuclear reprogramming efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.